SecBot SecBot

ELAN drug pipeline

Elanco Animal Health Inc · 1 rated drug
$26.41
−1.4% 1-day · Nov 16
Next catalyst
None dated
No dated FDA catalyst on file
Typical move on FDA news
No history
No past FDA events with prices
IV rank
No data
No current options data
Rated drugs
1
1 neutral
Phase 3 trials
0
0 with results posted

Drugs

soonest catalyst first
● neutral
Impact
PhaseApproved/Marketed
Time to marketAlready launched and marketed in Europe (Spain, Portugal, Austria) since 2023-2024.

AdTab lotilaner Updated Nov 9

What to watch

AdTab is a minor regional brand extension of Elanco's lotilaner (Credelio) franchise, launched in select European markets. It faces heavy competition from established flea/tick brands (Bravecto, NexGard, Simparica) and Elanco's own Credelio line. No upcoming binary catalysts exist for this specific product; watch Elanco's broader pet health portfolio (Credelio Quattro, Zenrelia) for material drivers.

Bull case
  • Lotilaner is a proven, effective active ingredient with FDA approval in the US under the Credelio brand and a strong safety profile.
  • Elanco's broader pet health portfolio is growing: Q3 2026 revenue rose 11% YoY to $1.265B, and the company raised its full-year 2026 outlook.
  • Analyst consensus is bullish: 19 of 22 analysts rate ELAN Buy or Strong Buy, with a mean price target of $30.69 (19% upside from $25.74).
Bear case
  • AdTab is a minor regional brand confined to a few European markets, competing against well-established flea/tick brands like Bravecto (Merck), NexGard (Boehringer), and Simparica (Zoetis), as well as Elanco's own Credelio.
  • Elanco faces a consumer price-fixing class action lawsuit over its flea and tick product market practices, which introduces legal overhang.
  • Elanco carries significant debt; the company sold $295M in future lotilaner royalty rights in 2025 to accelerate debt repayment, signaling cash needs.